Clinical Read2026-06-02

TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) - (ProstACT)

Telix Pharmaceuticals LimitedTLX
Indication
Prostate Cancer
Stage
phase3
Event
Phase 3